Seed germination has many impacts on the uses of seeds, and is an important subject for study. Seed germination is regulated at both transcriptional and post-transcriptional levels. Therefore, it is important to study how polyadenylation regulates gene expression during seed germination. To this end, a modified Illumina GAIIx sequencing protocol (described in Chapter Two) was developed that allows deep coverage of poly(A) site position and distribution. Alternative polyadenylation (APA) regulates gene expression by choosing one potential poly(A) site on a precursor RNA consequentially shortening/lengthening the mRNA relative to other possible sites. To further explore this phenomenon, genes affected by APA during seed germination and other developmental stages were identified (Chapter Three). These genes were categorized based on the location of poly(A) sites. Several genes were chosen to demonstrate how APA, especially that occurring in the coding regions and 5’ untranslated regions, might down regulate gene expression by generating truncated transcripts. In animal oocytes, maternally-derived mRNAs are stored with short poly(A) tails and reactivated by the cytoplasmic polyadenylation complex. It has been reported that seeds also contain stored mRNAs. Moreover, germination and its completion are less sensitive to de novo transcription inhibitors than to poly(A) polymerase inhibitors. Together, these considerations suggest that stored RNA without or with a short poly(A) tail (stored, unadenylated RNA) may be present in dry seed and function in seed germination upon reactivation by cytoplasmic polyadenylation. To further explore this, in Chapter Four, mRNA polyadenylation was studied through the course of germination using a combination of transcriptional inhibitors and the modified sequencing protocol described in Chapter Two. 273 putative stored, unadenylated RNAs were identified. Gene ontology analysis revealed that genes whose products are involved in translation are overrepresented; these genes encode 21 60S- and 10 40S-ribosomal proteins. These results indicate that transcripts whose products are involved in translation might be a major component of the stored, unadenylated RNA pool and, more importantly, translation might be the first cellular process to be activated during seed germination.

The link between polyadenylation (pA) and various biological, behavioral, and pathological events of eukaryotes underlines the need to develop in vivo polyadenylation assay methods for characterization of the cis-acting elements, trans-acting factors and environmental stimuli that affect polyadenylation efficiency and/or relative usage of two alternative polyadenylation (APA) sites. The current protein-based CAT or luciferase reporter systems can measure the polyadenylation efficiency of a single pA site or candidate cis element but not the choice of two APA sites. To address this issue, we developed a set of four new bicistronic reporter vectors that harbor either two luciferase or fluorescence protein open reading frames connected with one Internal Ribosome Entry Site (IRES). Transfection of single or dual insertion constructs of these vectors into mammalian cells demonstrated that they could be utilized not only to quantify the strength of a single candidate pA site or cis element, but also to accurately measure the relative usage of two APA sites at both the mRNA (qRT-PCR) and protein levels. This represents the first reporter system that can study polyadenylation efficiency of a single pA site or element and regulation of two APA sites at both the mRNA and protein levels.

No description available.

La plupart des gènes humains codants génèrent des transcrits alternatifs (isoformes) par épissage alternatif (alternative splicing, AS) et polyadénylation alternative (APA) en général dans la région codante et la région 3’ non traduite (3’UTR), respectivement. Le rôle de l’AS et la 3’UTR-APA est de plus en plus reconnu dans l’oncogenèse. En particulier, des réseaux d’AS connectant des facteurs d’épissage et des variants d’épissage ont récemment été identifiés. L’AS est aussi largement régulé par les agents anticancéreux génotoxiques, tel que la doxorubicine et le cisplatine (induisant des différents types de lésions sur l’ADN), qui sont régulièrementt utilisés dans les traitements du cancer du sein et du poumon non-à-petites-cellules (non-small-cell lung cancer, NSCLC), respectivement. Étant donné l’apparition fréquente de résistances aux chimiothérapies, comprendre les mécanismes sous-jacents est crucial pour surmonter ce problème clinique. Il existe des exemples d’évènements d’AS associés à la résistance aux agents anticancéreux, mais l’implication des facteurs d’épissage et des réseaux d’AS est très peu connue. De plus, une étude précédente a démontré que la doxorubicine réprime un grand groupe d’exon terminaux alternatifs (alternative last exons, ALE), qui correspondent à l’utilisation de sites de polyadénylation introniques (intronic polyadenylation, IPA). Les ALEs ont un rôle émergent dans le cancer, mais on ne sait encore que très peu sur leur régulation par d’autres agents anticancéreux, tel que le cisplatine. Afin de mieux comprendre le rôle des régulations d’AS et d’APA dans la réponse et la résistance cellulaire à la chimiothérapie, mon projet de thèse avait deux objectifs principaux : 1) déterminer l’étendue, les réseaux régulateurs, et les fonctions des régulations d’AS dans la résistance à la doxorubicine des cellules de cancer du sein, et 2) déterminer l’étendue, les mécanismes, et l’impact des régulations d’ALE en réponse au cisplatine dans des cellules de NSCLC. Dans la première partie, j’ai identifié par RNA-seq des milliers d’évènements d’AS et des dizaines de facteurs d’épissage régulés dans un modèle cellulaire de cancer du sein ER+ résistant à la doxorubicine. Par un miniscreen siARN, j’ai identifié deux facteurs, ZRANB2 et SYF2, impliqués dans la résistance à la doxorubicine. D’autres analyses RNA-seq ont révélé les évènements d’AS régulés par ces deux facteurs peu étudiés, ainsi que leur convergence vers l’exon 5 alternatif de l’oncogène ECT2. La déplétion de ZRANB2, SYF2, et du variant ECT2-ex5 réduit l’arrêt en phase S induit par la doxorubicine et la résistance des cellules. De plus, un niveau élevé d’inclusion de l’exon 5 d’ECT2 corrèle avec une mauvaise survie spécifiquement de patientes ER+ traitées par chimiothérapie. Dans la deuxième partie, j’ai identifié par 3’-seq que le traitement cisplatine (mais pas oxaliplatine) induit des ALEs/IPAs dans des milliers de gènes enrichis en gènes de cycle et de mort cellulaire. Cet effet est lié à une inhibition de la processivité de l’élongation dans les longs gènes. Une analyse 3’-seq sur polysomes m’a permis de montrer que ces régulations d’ALEs impactent le traductome, et a révélé un groupe d’isoformes particulièrement courtes peu efficacement traduites, dont un transcrit connu avec une fonction non-codante. En conclusion, j’ai pu identifier durant ma thèse un nouveau réseau d’AS impliqué dans la résistance à la doxorubicine des cancers du sein ER+, et une importante régulation d’ALEs impactant le traductome en réponse au cisplatine dans des cellules NSCLC. Ces travaux améliorent notre compréhension du rôle de l’AS et des ALE/IPA dans la réponse et la résistance cellulaire à la chimiothérapie anticancéreuse. Au plus long terme, les transcrits alternatifs et les régulateurs identifiés constituent des biomarqueurs candidats de chimiorésistance. / Most human coding genes generate alternative transcripts (isoforms) through alternative splicing (AS) and alternative polyadenylation (APA), most often within the coding region and the 3’ untranslated region (3’UTR), respectively. Both AS and 3’UTR-APA regulations have been increasingly involved in oncogenesis. In particular, AS networks connecting oncogenic splicing factors and oncogenic splicing variants have been recently identified. AS is also widely regulated by genotoxic anticancer drugs, like doxorubicin and cisplatin that induce different types of DNA lesions and are widely used in breast cancer and non-small-cell lung cancer (NSCLC) therapy, respectively. Given the frequent occurrence of resistance to chemotherapy, understanding the underlying mechanisms is crucial to overcome this major issue. There are examples of AS events associated with anticancer drug resistance, but very little is known about the splicing factors and therefore the AS networks involved. In addition, a previous study showed that doxorubicin represses a large set of alternative last exons (ALE) corresponding to the use of intronic polyadenylation (IPA) sites. ALEs have an emerging role in cancer, but little is known about its regulation by other anticancer drugs, like cisplatin. In order to better understand the role of AS and APA regulation in cell response and resistance to chemotherapy, my PhD project had two main aims: 1) determine the extent, regulatory networks and function of AS regulation in breast cancer cell resistance to doxorubicin, and 2) determine the extent, mechanism and impact of ALE regulation in response to cisplatin in NSCLC cells. In the first part, I identified by RNA-seq thousands of AS events and dozens of splicing factors regulated in a cell model of acquired resistance to doxorubicin in ER+ breast cancer. Through an siRNA miniscreen, I found two splicing factors, ZRANB2 and SYF2, involved in doxorubicin resistance. Further RNA-seq analyses revealed the AS events regulated by depletion of these poorly characterized splicing factors, and their convergence on the alternative exon 5 of the oncogene ECT2. Depletion of ZRANB2, SYF2 and the ECT2-Ex5 variant reduces doxorubicin-induced S phase arrest and doxorubicin resistance. In addition, high inclusion levels of ECT2-Ex5 correlate with poor survival specifically in ER+ breast cancer treated with chemotherapy. In the second part, I found by 3’-seq that in NSCLC cell treatment with cisplatin (but not oxaliplatin) induces ALE/IPA in thousands of genes enriched in cell cycle and cell death. This effect is linked to an inhibition of transcription elongation processivity in long genes. 3’-seq analysis on polysomes showed that this ALE regulation impacts the translatome, and revealed a set of particularly short isoforms that were inefficiently translated, including a transcript with a non-coding function. In conclusion, during my thesis, I could identify a novel AS network involved in doxorubicin resistance in ER+ breast cancer, and widespread ALE regulation impacting the translatome in lung cancer cisplatin response. This work increases our understanding of AS and IPA role in cell response and resistance to anti-cancer chemotherapy. In the longer term, the identified alternative transcripts and regulators constitute candidate biomarkers of chemoresistance.

Huntington’s disease is a neurodegenerative disorder caused by expansion of the CAG repeat in huntingtin exon 1. Early studies demonstrated the huntingtin gene is transcribed into two 3′UTR isoforms in normal human tissue. Decades later, researchers identified a truncated huntingtin mRNA isoform in disease but not control human brain. We speculated the amount of huntingtin 3′UTR isoforms might also vary between control and Huntington’s disease brains. We provide evidence that the abundance of huntingtin 3′UTR isoforms, including a novel mid-3′UTR isoform, differs between patient and control neural stem cells, fibroblasts, motor cortex, and cerebellum. Both alleles of huntingtin contribute to isoform changes. We show huntingtin 3′UTR isoforms are metabolized differently. The long and mid isoforms have shorter half-lives, shorter polyA tails, and more microRNA and RNA binding protein sites than the short isoform. 3′UTR Isoform changes are not limited to huntingtin. Isoforms from 11% of genes change abundance in Huntington’s motor cortex. Only 17% of genes with isoform alterations are differentially expressed in disease tissue. However, gene ontology analysis suggests they share common pathways with differentially expressed genes. We demonstrate knockdown of the RNA binding protein CNOT6 in control fibroblasts results in huntingtin isoform changes similar to those in disease fibroblasts. This study further characterizes Huntington’s disease molecular pathology and suggests RNA binding protein expression may influence mRNA isoform expression in the Huntington’s disease brain.

No description available.

No description available.

京都大学 / 新制・課程博士 / 博士(理学) / 甲第24082号 / 理博第4849号 / 新制||理||1694(附属図書館) / 京都大学大学院理学研究科生物科学専攻 / (主査)准教授 柘植 知彦, 教授 森 和俊, 教授 川口 真也 / 学位規則第4条第1項該当 / Doctor of Science / Kyoto University / DGAM

High-throughput genomic datasets obtained from microarray or sequencing studies have revolutionized the field of molecular biology over the last decade. The complexity of these new technologies also poses new challenges to statisticians to separate biological relevant information from technical noise. Two methods are introduced that address important issues with normalization of array comparative genomic hybridization (aCGH) microarrays and the analysis of RNA sequencing (RNA-Seq) studies. Many studies investigating copy number aberrations at the DNA level for cancer and genetic studies use comparative genomic hybridization (CGH) on oligo arrays. However, aCGH data often suffer from low signal to noise ratios resulting in poor resolution of fine features. Bilke et al. showed that the commonly used running average noise reduction strategy performs poorly when errors are dominated by systematic components. A method called pcaCGH is proposed that significantly reduces noise using a non-parametric regression on technical covariates of probes to estimate systematic bias. Then a robust principal components analysis (PCA) estimates any remaining systematic bias not explained by technical covariates used in the preceding regression. The proposed algorithm is demonstrated on two CGH datasets measuring the NCI-60 cell lines utilizing NimbleGen and Agilent microarrays. The method achieves a nominal error variance reduction of 60%-65% as well as an 2-fold increase in signal to noise ratio on average, resulting in more detailed copy number estimates. Furthermore, correlations of signal intensity ratios of NimbleGen and Agilent arrays are increased by 40% on average, indicating a significant improvement in agreement between the technologies. A second algorithm called gamSeq is introduced to test for differential gene expression in RNA sequencing studies. Limitations of existing methods are outlined and the proposed algorithm is compared to these existing algorithms. Simulation studies and real data are used to show that gamSeq improves upon existing methods with regards to type I error control while maintaining similar or better power for a range of sample sizes for RNA-Seq studies. Furthermore, the proposed method is applied to detect differential 3' UTR usage.

No description available.